Nektar Therapeutics Sets Sights on Revolutionizing Treatment Paradigms with Rezpegaldesleukin
San Francisco, CA - Nektar Therapeutics has made significant strides in 2025, and its momentum carries over into the new year. The company's latest financial results conference call provided a glimpse into the promising prospects of rezpegaldesleukin, a novel T-regulatory cell biologic being developed for atopic dermatitis, alopecia areata, and type 1 diabetes.
According to Howard Robin, President and CEO of Nektar Therapeutics, 2025 marked a pivotal year for the company. He noted that the successful outcome of rezpegaldesleukin's phase two studies in atopic dermatitis and alopecia areata validated the therapeutic potential of the novel regulatory T-cell mechanism.
The results from these studies showed clinically meaningful outcomes in both disease settings, with significant durability of efficacy observed in the 36-week maintenance portion of REZOLVE-AD in atopic dermatitis. Monthly or quarterly dosing of rezpegaldesleukin during this period demonstrated a deepening response with increases in EASI 75, EASI 90, and an up to five-fold increase in EASI 100 scores.
The potential for rezpegaldesleukin to disrupt the treatment paradigm in atopic dermatitis is substantial. The market for biologics in this disease setting is expected to grow to approximately $35 billion by the mid-2030s, driven by the rapid adoption of these therapies. However, a significant portion of patients fail to respond or lose treatment effect over time with IL-13-based approaches.
This presents an opportunity for rezpegaldesleukin, which could offer a differentiated efficacy and safety profile with a better dosing regimen and the potential to provide complete clearance of disease over time. In alopecia areata, where approved JAK inhibitors carry significant safety risks and monitoring burdens, rezpegaldesleukin offers a promising alternative.
The company believes that rezpegaldesleukin's unique mechanism sets it apart from other late-stage novel MOAs being advanced to BLA filing, putting it in a lead position. This confidence is reflected in the company's continued investment in its immunology and inflammation pipeline programs.
